Boundless Bio

Vision

Unbound by convention and bound to save lives, we envision a world in which patients with ecDNA-driven cancers have access to powerful anti-cancer therapies that improve and extend their lives.

Approach

Boundless Bio is the first company committed to developing transformative therapeutics for patients with oncogene amplified cancers driven by extrachromosomal DNA (ecDNA). ecDNA are circular DNA, physically distinct from chromosomes, that encode oncogenes and drive both oncogenesis as well as resistance to current therapeutic approaches across many types of cancer. Leveraging a proprietary platform called Spyglass, Boundless is advancing a new wave of cancer therapy, ecDNA-directed therapies (ecDTx), that disrupt the formation or function of ecDNA and has the potential to address a large and high unmet need population of patients that typically do not benefit from currently approved targeted therapies and immunotherapies.

Boundless Bio is addressing

• Leap 04 / Prevent and cure cancer